Royalty Pharma PLC $RPRX Stock Purchased by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management increased its Royalty Pharma position by 28.2% in the third quarter, adding 256,841 shares. It now owns 1.17 million shares worth approximately $68.2 million, or 0.20% of the company.
• Institutional investors own 54.35% of Royalty Pharma, while insiders sold 208,252 shares worth $12.3 million over the past 90 days through pre-arranged trading plans.
• Royalty Pharma shares opened at $63.75, near their 12-month high, and the company declared a quarterly dividend of $0.235 per share, equivalent to a 1.5% annual yield. Analysts maintain a consensus “Buy” rating with a $61.57 target price.

Robeco Institutional Asset Management B.V. increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 28.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,168,427 shares of the biopharmaceutical company's stock after buying an additional 256,841 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.20% of Royalty Pharma worth $68,189,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Royalty Pharma by 4.2% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 215,483 shares of the biopharmaceutical company's stock valued at $12,576,000 after purchasing an additional 8,718 shares in the last quarter. USA Financial Formulas acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at $192,000. Triasima Portfolio Management inc. grew its position in shares of Royalty Pharma by 23.7% in the 3rd quarter. Triasima Portfolio Management inc. now owns 223,527 shares of the biopharmaceutical company's stock valued at $13,045,000 after buying an additional 42,817 shares during the last quarter. Curated Wealth Partners LLC purchased a new position in shares of Royalty Pharma in the 3rd quarter valued at $205,000. Finally, NorthCrest Asset Manangement LLC grew its position in shares of Royalty Pharma by 41.3% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 6,705 shares of the biopharmaceutical company's stock valued at $377,000 after buying an additional 1,961 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Royalty Pharma

In other news, EVP Marshall Urist sold 4,126 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the sale, the executive vice president owned 270,401 shares of the company's stock, valued at $15,826,570.53. This trade represents a 27.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 208,252 shares of company stock valued at $12,324,407 over the last ninety days. Corporate insiders own 18.84% of the company's stock.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $63.75 on Friday. The firm's fifty day simple moving average is $59.72 and its 200-day simple moving average is $56.16. The stock has a market capitalization of $36.66 billion, a price-to-earnings ratio of 43.97, a PEG ratio of 1.70 and a beta of 0.42. Royalty Pharma PLC has a 12 month low of $35.92 and a 12 month high of $64.38. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.27 by $0.05. The firm had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. As a group, equities analysts forecast that Royalty Pharma PLC will post 5.29 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.5%. Royalty Pharma's payout ratio is currently 64.83%.

Analyst Ratings Changes

A number of brokerages recently weighed in on RPRX. Wall Street Zen cut shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 26th. JPMorgan Chase & Co. lifted their target price on Royalty Pharma from $58.00 to $62.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. The Goldman Sachs Group reissued a "buy" rating and issued a $66.00 target price on shares of Royalty Pharma in a report on Thursday, August 6th. Bank of America reissued a "buy" rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. Finally, Weiss Ratings raised Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, September 14th. Eight equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $61.57.

Royalty Pharma Company Profile

Royalty Pharma plc NASDAQ: RPRX is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.